ClinicalTrials.gg
TerminatedNCT04624646CANDLE-AFUpdated Oct 13, 2026

Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke

An interventional study of Ambulatory Holter monitoring and Discontinuous monitoring in Atrial Fibrillation, Ischemic Stroke and Transient Ischemic Attack, sponsored by Ewha Womans University Mokdong Hospital. Terminated at 7 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ewha Womans University Mokdong Hospital · Not applicable, Interventional, and Screening

How we know

Why this study was terminated
Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.
Updated Sep 30, 2026Now TerminatedPrimary completion moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.

Enrollment
66th of 144
338 · median 300
Started
2020
with 11 others
No phase
91 of 209
36 open now
Registered
127th of 209
by date
Lead sponsor
8 of 209
Ewha Womans University Mokdong Hospital

Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 66th largest by enrollment of the 144 interventional ones that give a count, is one of 12 that started in 2020, is one of 91 with no phase, and was the 127th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Atrial Fibrillation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) detected after ischemic stroke has immediate therapeutic implications, because it prompts a switch from antiplatelet to anticoagulant therapy. The conventional method used to screen for AF in patients whose stroke has no identified cause (cryptogenic stroke) is 24-hour Holter monitoring. CANDLE-AF is a multicenter, open-label, randomized trial comparing three noninvasive monitoring strategies over 12 months in patients with cryptogenic ischemic stroke or transient ischemic attack and no known AF: physician-directed standard care (at least one 24- to 72-hour Holter recording), scheduled 72-hour single-lead patch ECG monitoring repeated at 1, 3, 6, and 12 months, and twice-daily 30-second handheld single-lead ECG recording with a smartphone-based device for 12 months. The primary outcome is detection of AF lasting 30 seconds or longer within 12 months.

03

Conditions studied

  • Atrial Fibrillation
  • Ischemic Stroke
  • Transient Ischemic Attack

Keywords

  • Atrial fibrillation
  • Ischemic Stroke
  • Transient Ischemic Attack
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Ischemic stroke or with no identified cause (cryptogenic) after standard etiologic evaluation, admitted to the neurology department of a participating center
  • No history of atrial fibrillation and no atrial fibrillation on the admission or on continuous in-hospital telemetry
  • Informed of implantable cardiac monitoring according to guidelines and declined it
  • Written

Exclusion criteria

Exclusion Criteria:

  • Identified etiology of the stroke or
  • Known or documented atrial fibrillation, including prior atrial fibrillation with restored sinus rhythm
  • Pacemaker, implantable cardioverter-defibrillator, or other implanted electrical device
  • Unable to use the smartphone-based recorder alone or with the help of others
  • Pregnancy or lactation - Skin cancer, rash, skin disease, keloid, or injury at the patch site (current or history)
  • less than 1 year
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
338 participants (actual)

Study arms

  • Active comparator
    Conventional Holter Monitoring Group

    Physician-directed standard care, including at least one 24- to 72-hour Holter recording; further rhythm monitoring during the 12-month follow-up at the treating physician's discretion. Anticoagulation is recommended when AF is detected, at the treating physician's discretion.

    Device: Ambulatory Holter monitoring

  • Experimental
    Discontinuous Monitoring Group

    Standard care plus twice-daily 30-second single-lead ECG recordings with a smartphone-based handheld recorder (KardiaMobile, AliveCor) for 12 months, transmitted through the smartphone application to a cardiac core laboratory. Anticoagulation is recommended when AF is detected, at the treating physician's discretion.

    Device: Ambulatory Holter monitoring · Device: Discontinuous monitoring

  • Experimental
    Single-lead Continuous Patch Group

    Standard care plus continuous 72-hour single-lead adhesive patch ECG monitoring (mobiCARE-MC100, Seers Technology) at 1, 3, 6, and 12 months after enrollment, transmitted to a cardiac core laboratory. Anticoagulation is recommended when AF is detected, at the treating physician's discretion.

    Device: Ambulatory Holter monitoring · Device: Continuous single-lead ECG Patch

Interventions

  • DeviceAmbulatory Holter monitoring

    At least one 24- to 72-hour ambulatory Holter recording; additional monitoring at the physician's discretion.

    Also known as: Standard care

  • DeviceDiscontinuous monitoring

    Twice-daily 30-second handheld single-lead ECG recording for 12 months.

    Also known as: iECG, Kardiamobile

  • DeviceContinuous single-lead ECG Patch

    72-hour continuous single-lead patch ECG monitoring at 1, 3, 6, and 12 months (four sessions)

    Also known as: Patch monitoring, Mobicare, mobiCARE-MC100

06

What researchers measure

Primary outcomes

  1. Detection of atrial fibrillation lasting 30 seconds or longer

    First detection of AF lasting at least 30 seconds on any ECG recording (assigned device, Holter, 12-lead ECG, or clinical recording), confirmed by physician review

    Time frame: Within 12 months after randomization

Secondary outcomes

  1. Recurrent ischemic stroke or transient ischemic attack

    Time frame: Within 12 months after randomization

  2. Major adverse cardiovascular and cerebrovascular events (MACCE)

    composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death

    Time frame: Within 12 months after randomization

  3. Initiation of oral anticoagulation following AF detection

    Initiation of oral anticoagulation following AF detection

    Time frame: Within 12 months after randomization

  4. All-cause readmission

    Time frame: Within 12 months after randomization

  5. All-cause death

    All-cause death

    Time frame: Within 12 months after randomization

Other outcomes

  1. Major bleeding

    Fatal or overt bleeding with a drop in hemoglobin level of at least 2 g/dL or requiring transfusion of at least 2 units packed blood cells, or critical anatomical site hemorrhage (e.g., intracranial, retroperitoneal)

    Time frame: Within 12 months after randomization

07

Study locations

7 sites
  • Ewha Womans University Seoul Hospital
    Gangseo, Seoul 07985, South Korea
  • Hanyang University Seoul Hospital
    Seongdong, Seoul 04763, South Korea
  • Korea University Guro Hospital
    Seoul, Seoul 08308, South Korea
  • Ewha Womans University Mokdong Hospital
    Yangcheon, Seoul 07985, South Korea
  • Daegu Catholic University Medical Center
    Daegu, South Korea
  • Kyung Hee University Hospital
    Seoul, 02447, South Korea
  • Yonsei University Health System, Severance Hospital
    Seoul, 06273, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results, a data dictionary defining each field, and the statistical analysis code will be made available to qualified investigators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 12 months after publication of the primary results, with no end date

Access criteria: Requests with a methodologically sound proposal should be directed to the corresponding author (parkjb@ewha.ac.kr). Access requires approval by the institutional review board of Ewha Womans University Medical Center and a signed data access agreement; data will be shared only for analyses within the scope of the informed consent.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2020 to primary completion in Jul 2026, 67 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2025 → Jul 2026 and completion Nov 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2020
First posted
Nov 12, 2020
StartActual
Nov 17, 2020
Primary completionActual
Jul 8, 2026was Nov 2025
CompletionActual
Jul 8, 2026was Nov 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.
changed Sep 30, 2026
Sites
1 site added, 3 sites removed
Show site
  • Korea University Guro Hospital · Seoul, South Korea
Show 3 removed
  • Yonsei University Health System, Yongin Severance Hospital · Yongin, South Korea
  • Gachon University Gil Hospital · Incheon, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
Sep 30, 2026
Primary completion
Nov 1, 2025→Jul 8, 2026
Sep 30, 2026
Study completion
Nov 15, 2026→Jul 8, 2026 (actual)
Sep 30, 2026
Enrollment
337→338
Sep 30, 2026
Eligibility
Minimum age 20 Years→18 Years; Maximum age 80 Years→none; Criteria largely rewritten (14 changes)
What changed in the criteria
Inclusion criteria
  • RemovedNewly diagnosed brain infarction
  • RemovedNo history and diagnosis of atrial fibrillation at the time of admission
  • RemovedRejected implantable loop recorder
  • AddedAge 18 years or older
  • AddedIschemic stroke or transient ischemic attack with no identified cause (cryptogenic) after standard etiologic evaluation, admitted to the neurology department of a participating center
  • AddedNo history of atrial fibrillation and no atrial fibrillation on the admission ECG or on continuous in-hospital telemetry
  • AddedInformed of implantable cardiac monitoring according to guidelines and declined it
  • EditedInformedWritten informed consent
Exclusion criteria
  • AddedIdentified etiology of the stroke or transient ischemic attack
  • AddedKnown or documented atrial fibrillation, including prior atrial fibrillation with restored sinus rhythm
  • AddedPacemaker, implantable cardioverter-defibrillator, or other implanted electrical device
  • EditedCannotUnable to use KardiaMobile systemthe smartphone-based recorder alone or with the help of others
  • AddedPregnancy or lactation - Skin cancer, rash, skin disease, keloid, or injury at the patch site (current or history)
  • AddedLife expectancy less than 1 year
Sep 30, 2026
Interventions
Added Device: Ambulatory Holter monitoring; removed Device: 24-hour Holter monitoring
Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Atrial fibrillation detection rateNow Detection of atrial fibrillation lasting 30 seconds or longerTime frame: Until 1 year after stroke → Within 12 months after randomization
Sep 30, 2026
Secondary outcomes
1 edited, 2 time frame changed, 3 added, 2 removed
What changed in the outcomes
  • EditedMajor adverse cardiaccardiovascular and cerebrovascular eventevents (MACCE)Time frame: Until 1 year after stroke → Within 12 months after randomization
  • AddedRecurrent ischemic stroke or transient ischemic attackTime frame: Within 12 months after randomization
  • AddedInitiation of oral anticoagulation following AF detectionTime frame: Within 12 months after randomization
  • AddedAll-cause readmissionTime frame: Within 12 months after randomization
  • RemovedChange from antiplatelet therapy to anticoagulants following AF detectionTime frame: Until 1 year after stroke
  • RemovedRe-admissionTime frame: Until 1 year after stroke
  • Time frameAll-cause deathUntil 1 year after stroke → Within 12 months after randomization
  • Time frameother outcomeMajor bleedingUntil 1 year after stroke → Within 12 months after randomization
Sep 30, 2026
Sponsor
Collaborators added: National Research Foundation of Korea·Korea Medical Device Development Fund·AliveCor
Sep 30, 2026
Show all 2 updates
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details
  2. Sep 30, 2026
    Active, not recruiting→Terminated
    Why stopped Enrollment was closed early in July 2025 because of slow recruitment (338 of 600 planned participants; 324 were required for the superiority comparison). The 12-month follow-up period for all randomized participants ended in July 2026.
    1 site added, 3 sites removed
    Show site
    • Korea University Guro Hospital · Seoul, South Korea
    Show 3 removed
    • Yonsei University Health System, Yongin Severance Hospital · Yongin, South Korea
    • Gachon University Gil Hospital · Incheon, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    Primary completion Nov 1, 2025→Jul 8, 2026
    Study completion Nov 15, 2026→Jul 8, 2026 (now actual)
    Enrollment 337→338
    Eligibility Minimum age 20 Years→18 Years; Maximum age 80 Years→none; Criteria largely rewritten (14 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedNewly diagnosed brain infarction
    • RemovedNo history and diagnosis of atrial fibrillation at the time of admission
    • RemovedRejected implantable loop recorder
    • AddedAge 18 years or older
    • AddedIschemic stroke or transient ischemic attack with no identified cause (cryptogenic) after standard etiologic evaluation, admitted to the neurology department of a participating center
    • AddedNo history of atrial fibrillation and no atrial fibrillation on the admission ECG or on continuous in-hospital telemetry
    • AddedInformed of implantable cardiac monitoring according to guidelines and declined it
    • EditedInformedWritten informed consent
    Exclusion criteria
    • AddedIdentified etiology of the stroke or transient ischemic attack
    • AddedKnown or documented atrial fibrillation, including prior atrial fibrillation with restored sinus rhythm
    • AddedPacemaker, implantable cardioverter-defibrillator, or other implanted electrical device
    • EditedCannotUnable to use KardiaMobile systemthe smartphone-based recorder alone or with the help of others
    • AddedPregnancy or lactation - Skin cancer, rash, skin disease, keloid, or injury at the patch site (current or history)
    • AddedLife expectancy less than 1 year
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Atrial fibrillation detection rateNow Detection of atrial fibrillation lasting 30 seconds or longerTime frame: Until 1 year after stroke → Within 12 months after randomization
    Secondary outcomes 1 edited, 2 time frame changed, 3 added, 2 removed
    What changed in the outcomes
    • EditedMajor adverse cardiaccardiovascular and cerebrovascular eventevents (MACCE)Time frame: Until 1 year after stroke → Within 12 months after randomization
    • AddedRecurrent ischemic stroke or transient ischemic attackTime frame: Within 12 months after randomization
    • AddedInitiation of oral anticoagulation following AF detectionTime frame: Within 12 months after randomization
    • AddedAll-cause readmissionTime frame: Within 12 months after randomization
    • RemovedChange from antiplatelet therapy to anticoagulants following AF detectionTime frame: Until 1 year after stroke
    • RemovedRe-admissionTime frame: Until 1 year after stroke
    • Time frameAll-cause deathUntil 1 year after stroke → Within 12 months after randomization
    • Time frameother outcomeMajor bleedingUntil 1 year after stroke → Within 12 months after randomization
    Interventions Added Device: Ambulatory Holter monitoring; removed Device: 24-hour Holter monitoring
    Sponsor Collaborators added: National Research Foundation of Korea·Korea Medical Device Development Fund·AliveCor
    + 4 other changes: identifiers, verification date, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04624646
Lead sponsor
Ewha Womans University Mokdong Hospital
Collaborators
Korea Health Industry Development Institute, National Research Foundation of Korea, Korea Medical Device Development Fund, AliveCor
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Nov 17, 2020
Primary completion
Jul 8, 2026
Completion
Jul 8, 2026
Last update
Oct 13, 2026

Study contacts

Junbeom Park, M.D., PhD.
principal investigator · Ewha Womans University Mokdong Hospital
Tae-Jin Song, MD
principal investigator · Ewha Womans University Seoul Hospital
Dong-Hyeok Kim, MD
principal investigator · Ewha Womans University Seoul Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion